Enter Your Current Weight
You could lose this much weight (lbs):
*During clinical trials for Saxenda and Wegovy as treatments for obesity (BMI ≥30) and overweight (BMI ≥27) in individuals with at least one weight-related condition, non-diabetic participants who successfully completed the trials experienced an average reduction of 9% and 15% in their body weight, respectively. These results were achieved when the medications were used in conjunction with diet and exercise, in contrast to a weight loss of 3.5% and 2.4% observed in individuals solely relying on diet and exercise.
Safety information: GLP-1 medications are prescribed for the treatment of obesity or overweight in conjunction with diet and exercise regimens. However, it’s important to note that these medications can lead to serious side effects, including the potential development of thyroid tumors. If you or your family have a history of a specific type of thyroid cancer known as MTC or MEN 2, it is advised not to use these medications. For further details on critical warnings and safety considerations, please refer to additional safety information.
On average, people who took a GLP-1 medication such as Wegovy lose around 15% of their weight within a year.
Get GLP-1 weight loss medication based on your current weight and your past medical history if medically appropriate.
Saxenda and Wegovy are weekly shots that are FDA approved for weight loss. Ozempic is FDA-approved for the treatment of type 2 diabetes but may be prescribed off-label for weight loss if deemed medically appropriate.
Also known as Wegovy®, Ozempic®, and compounded Semaglutide
Also known as Mounjaro® and compounded Tirzepatide
Also know as Saxenda® and compounded Liraglutide
Learn more about potential side effects for Wegovy, Ozempic, Mounjaro and Saxenda
Individuals without diabetes but with a BMI equal to or exceeding ≥30, or ≥27 alongside coexisting health conditions, exhibited an average weight reduction of 15% over the course of one year. This outcome was derived from a 68-week clinical study that investigated the effects of 2.4 mg semaglutide in conjunction with a calorie-restricted diet and heightened levels of physical activity
Starting your weight loss journey with NiceRx is fast and easy. The first step is sharing your health history and weight loss goals. You will only be billed if approved for a prescription by the healthcare provider.
If approved for the medical weight loss program, this is what you can expect.Get Started
Start by completing a short health survey to find out if GLP-1 medications may work for you.
Schedule your initial online consultation with your new licensed clinician.
Once your provider has results and determined if a GLP-1 medication is suitable, you will embark on the Weight Loss Program and continuous care from the provider.
Receive your medication at home and start losing weight.
You will have the option to meet with your licensed clinician on a monthly basis to discuss the treatment provided. You will receive a refill notification before your next shipment comes due.
You will receive everything you need to lose weight and keep it off.
Compounded semaglutide GLP-1 medication
The NiceRx Weight Loss Program costs $999 for a 3-month supply of GLP-1 medication. This price also includes the initial consultation with the doctor and up to 2 follow-up visits. Shipping is free and there are no additional fees.
NiceRx does not accept insurance. As well, there is no insurance required to join the program.
If your insurance won’t cover the cost of the medication, you may receive significant savings through the NiceRx Weight Loss Program.
Due to high demand, Novo Nordisk, the company behind Wegovy, Ozempic, and Saxenda, foresees shortages in the availability of these medications. They expect the demand for Wegovy to surpass the available supply. Patients might encounter challenges in obtaining Wegovy prescriptions at the doses of 0.25 mg, 0.5 mg, and 1 mg, as well as Saxenda prescriptions, throughout 2023 and potentially beyond. It has been observed that nearly half of the patients still face difficulties accessing the affected Wegovy and Saxenda doses even after waiting for a month.
NiceRx and its affiliated healthcare providers are taking additional measures to assist patients in their weight loss journey. We are helping patients to access compounded GLP-1 medications (e.g. compounded semaglutide) that are readily available while the brand name drugs are in shortage to assist with the continuity of treatment. Providers may adjust the treatment plan for patients if deemed clinically appropriate. These adjustments could involve prescribing alternative GLP-1 medications, working collaboratively on a personalized treatment plan, or suggesting modifications to diet, lifestyle, and fitness activities.
For patients starting the NiceRx Weight Loss Program, the initial steps remain unaffected by the supply issues. If a provider decides that a GLP-1 medication is suitable, the sooner a patient joins the program, the quicker our team can work towards assisting you with your weight loss journey.
Medical weight loss refers to a comprehensive and supervised approach to achieving weight loss under the guidance of healthcare professionals, typically involving physicians and other specialized medical personnel. This method differs from conventional weight loss programs in that it integrates medical expertise to address underlying health issues, such as obesity-related conditions or metabolic disorders.
Medical weight loss programs often include a combination of personalized diet plans, exercise regimens, behavioral therapy, and, when necessary, prescription medications if medically appropriate. The focus is on creating a tailored and sustainable weight loss plan that considers an individual’s unique health profile and medical history. Regular monitoring and adjustments are made to ensure the safety and effectiveness of the weight loss journey, making medical weight loss a more specialized and evidence-based approach than many commercial weight loss programs.
Doctors know that GLP-1 medications are effective at reducing food intake, appetite and hunger. These drugs also slow the movement of food from the stomach into the small intestine. As a result, you may feel full faster and longer, so you eat less, with the ultimate end result of promoting weight loss.
Mounjaro (tirzepatide) is an injectable prescription medicine that is used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes mellitus. It is a is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist.
Mounjaro is specifically indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
The starting dose is a 2.5 mg subcutaneous injection once a week, and after 4 weeks, increase it to 5 mg injected subcutaneously once weekly. If more glycemic control is necessary, consider increasing the dosage by 2.5 mg increments, but only after sticking with the current dose for at least 4 weeks. The highest dosage allowed is 15 mg subcutaneously once weekly. You can administer it at any time of the day, with or without meals. Inject it subcutaneously in the abdomen, thigh, or upper arm, and make sure to change the injection site with each dose.